alexa Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Secondary Progressive Multiple Sclerosis | OMICS International | Abstract
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Secondary Progressive Multiple Sclerosis

Lu Z1,2, Zhao H1,2, Xu J3, Zhang Z1, Zhang X1, Zhang Y1, Liu Z1,2 and Xu Y1,2*

1Department of Neurology, Drum Tower Hospital, Nanjing Medical University, Nanjing, Jiangsu, PR China

2Department of Neurology, Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjin, Jiangsu, PR China

3Department of Neurology, Brain Hospital, Nanjing, Jiangsu, PR China

Corresponding Author:
Yun Xu, MD, PhD
Department of Neurology, Affiliated Drum Tower Hospital
Nanjing University Medical School, 321 Zhongshan Road
Nanjing, Jiangsu, 210008, P. R. China
Tel: +86 25 83105208
Fax: +86 25 83317016
E-mail: [email protected]

Received Date: October 25, 2013; Accepted Date: November 25, 2013; Published Date: November 27, 2013

Citation: Lu Z, Zhao H, Xu J, Zhang Z, Zhang X, et al. (2013) Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Secondary Progressive Multiple Sclerosis. J Stem Cell Res Ther S6:002. doi:10.4172/2157-7633.S6-002

Copyright: © 2013 Lu Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: Multiple sclerosis (MS) is an irreversible and demyelinating disease of the brain and spinal cord that causes significant disability in young people. However, therapeutic options to effectively stop the pathological progression of MS are limited. This study aimed to evaluate the safety and efficacy of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in the treatment of secondary progressive multiple sclerosis.

Methods: Eight patients with secondary progressive multiple scleroses were recruited from May 2010 and December 2010. Participants received intrathecal intravenous injections of hUC-MSCs. All patients were evaluated by Expanded Disability Status Scale, frequency of relapse, lymphocyte classification, magnetic resonance imaging (MRI) characteristics and adverse events from before treatment to up to 18 months after the infusion.

Results: The study suggested that, among the eight cases, six showed therapeutic improvement after hUCMSCs treatment and in all eight patients, relapse frequencies decreased to 36.4% of those before the treatment (1.2 ± 0.5 vs. 3.3 ± 0.7, p<0.05). Flow cytometry assay (FACS) indicated that blood T cells and B cells were inhibited after treatment. MRI characteristics also showed decreased volume and severity of lesions, with few adverse events. Conclusion: hUC-MSCs can alleviate disability and reduce relapse of secondary progressive multiple sclerosis by modulating immune responses, which also had been proved to be safe in MS patients. These findings suggest that transplantation of hUC-MSCs may be a potential therapy for MS.


Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7